United Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Recent clinical trial successes position Tyvaso and ralinepag as leading therapies for pulmonary diseases, with rapid commercialization and significant revenue growth expected. The pipeline features innovative inhalers and organ manufacturing advances, while AI-driven models are streamlining drug development.
-
Strong double-digit growth is expected to continue, driven by robust Ralinepag data and new inhaled therapies. Ralinepag is projected to become a blockbuster, while Tyvaso's expansion into IPF and other indications offers significant market opportunities. Xenotransplantation and disciplined capital allocation further support long-term growth.
-
The Phase III ADVANCE OUTCOMES trial showed ralinepag significantly reduced clinical worsening in PAH patients, with robust efficacy across all subgroups and a favorable safety profile. Its once-daily dosing and tolerability position it as a potential frontline therapy, likely to expand the oral prostacyclin market.
-
IPF and super-prostacyclin are set to drive major growth, with Tyvaso showing game-changing results in IPF and ralinepag poised to lead in pulmonary hypertension. Expansion into orphan oncology and xenotransplantation further strengthens the pipeline.
Fiscal Year 2025
-
Record 2025 revenue surpassed $3B, driven by Tyvaso and Orenitram, with double-digit growth expected to continue. Three transformative product launches are planned by 2027, and a $4B run rate is targeted, excluding new launches.
-
Tyvaso and Tyvaso DPI drive robust growth, with resilience against new competitors and a $1B quarterly revenue run rate targeted by 2027. Strong IPF data and a broad pipeline, including organ transplantation, support long-term expansion.
-
Strong double-digit growth in Tyvaso, best-in-class IPF trial results, and pipeline progress underpin confidence in reaching a $4B revenue run rate by 2027. Xenotransplantation program achieved a first-in-human milestone, with further updates expected after initial cohort completion.
-
Record quarterly revenues of $800 million, up 7% year-over-year, driven by Tyvaso and Orenitram. Strong clinical progress in IPF and new product launches support a $4 billion revenue run rate by 2027, with continued growth expected in key segments.
-
The phase 3 TETON 2 study in IPF met its primary endpoint, with nebulized Tyvaso showing significant improvement in FVC and key secondary outcomes, including quality of life and clinical worsening, while maintaining a tolerable safety profile. Consistent efficacy was observed across patient subgroups.
-
The event highlighted robust clinical progress in pulmonary fibrosis and hypertension, with new therapies and devices advancing toward regulatory filings and commercialization. Expansion in organ manufacturing and xenotransplantation, strong IP protection, and disciplined capital allocation—including a $1B share repurchase—support sustained growth.
-
TETON-2 results for nebulized TYVASO in IPF showed unprecedented efficacy, supporting plans for label expansion and a dedicated Salesforce to address a multibillion-dollar market. A $1B share repurchase was launched, and the xenotransplant program is advancing with new facilities and clinical milestones.
-
Record Q2 2025 revenue of $799M marked 12th straight quarter of double-digit growth, led by Tyvaso DPI. Strong cash flow and a $1B share repurchase reflect confidence in future catalysts, with key clinical data expected in pulmonary fibrosis and hypertension.
-
Record Q1 revenue of $794M, up 17% year-over-year, driven by strong treprostinil product demand and robust pipeline progress. Double-digit growth is expected to continue, supported by strategic capital allocation and expansion into new indications.
-
Capital allocation remains focused on R&D, facility expansion, and shareholder returns, while Tyvaso DPI drives strong commercial growth with robust manufacturing capacity. Key clinical milestones include TETON and ADVANCE OUTCOMES trials, and the xenokidney program is set for its first transplant in 2024.
-
Strong commercial execution continues with Tyvaso and pipeline progress in IPF and PAH. Key clinical readouts are expected in 2024–2025, while payer contracting and product enhancements position the portfolio for growth amid new competition. Xenotransplantation capacity is expanding, with significant long-term revenue potential.
-
The conference highlighted robust financial growth, a multi-phase innovation strategy, and major clinical milestones in organ manufacturing and rare disease therapeutics. Facility expansion and disciplined capital allocation support ambitious revenue targets and ongoing shareholder returns.
Fiscal Year 2024
-
Record revenue growth of nearly 24% year-over-year was driven by strong performance across all major products and strategic investments in manufacturing and R&D. Continued double-digit growth is expected, with new clinical milestones and product launches anticipated in 2025.
-
Achieved a $3B revenue run rate with double-digit growth expected, driven by Tyvaso and portfolio expansion. Manufacturing and sales force capacity have scaled, with major clinical milestones in IPF and xenotransplantation targeted for 2025–2026.
-
Record Q3 revenue of $749M (up 23% YoY) driven by strong growth in Tyvaso, Orenitram, and Unituxin, with robust commercial execution and pipeline progress. Completed $1B share repurchase, maintained double-digit growth outlook, and advanced key clinical and regulatory milestones.
-
Strong commercial growth continues, led by PH-ILD and TYVASO, with expanding market penetration and investments in sales and education. Product differentiation and established relationships provide defenses against competition and generics. Pipeline advances in IPF and xenotransplantation offer significant future opportunities.
-
Capital allocation remains focused on business investment, BD, and share repurchases, with recent progress in all areas. Tyvaso DPI and PH-ILD markets show strong growth, supported by sales force expansion and new patient support initiatives. Pipeline advances in IPF and organ manufacturing offer significant future opportunities.
-
Record Q2 revenue of $715M marked 20% growth year-over-year, led by Tyvaso, Orenitram, Remodulin, and Unituxin. Strong commercial execution, ongoing clinical trials, and a robust capital allocation strategy support continued growth and innovation.
-
Leadership emphasized innovation in organ manufacturing and inhaled therapies, with Tyvaso DPI gaining market share and manufacturing capacity expanding. Organ assist and xenotransplantation programs are advancing toward clinical milestones, while capital allocation remains focused on growth and patient impact.